Skip to main content
. Author manuscript; available in PMC: 2024 Jul 1.
Published in final edited form as: Gynecol Oncol. 2023 May 26;174:262–272. doi: 10.1016/j.ygyno.2023.05.059

Figure 2. Endometrial cancer molecular classification according to the integrated clinical tumor-normal sequencing/immunohistochemistry-based and the conventional ProMisE approaches.

Figure 2.

A. TP53 mutations and p53 expression patterns by immunohistochemistry in endometrial cancers classified as of copy number-high molecular subtype. B. Sequencing-derived MSI-sensor scores and DNA mismatch repair (MMR) deficiency/ proficiency by immunohistochemistry in endometrial cancers classified as of MSI-H molecular subtype. C. Agreement of molecular subtype assignments using our integrated molecular and immunohistochemistry-based approach (top) and the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE; second row from top). Information on the TP53 mutation status, p53 immunohistochemistry, MSIsensor score and MMR immunohistochemistry are shown below.